Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,886.24
(
1.02%
)
US TECH 100
24,753.20
(
1.27%
)
Dow Jones
48,218.25
(
0.63%
)
Brent Oil
95.11
(
-0.38%
)
Bitcoin
74,410.87
(
-0.12%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Protector

Send PM Follow Ignore
Followers 140
Posts 11663
Boards Moderated 0
Alias Born 03/15/2011

Protector

Re: entdoc post# 267947

Sunday, 07/10/2016 7:36:35 PM

Sunday, July 10, 2016 7:36:35 PM

Post# of 347009
endoc, come on. Are you saying that AstraZeneca is going to run the Durvalumab+Bavituximab combo clinical trial, which is a immuno agent combination, in NSCLC just for the show. Because under your statement below that is all what is would be.

I was not hedging, but leaving open the small (small to the vanishing point) chance that Bavi could be used in combo with other immunology-oncology agents for advanced lung cancer.



Frowning eyebrows.

Peregrine Pharmaceuticals the Microsoft of Biotechnology! All In My Opinion. I am not advising anything, nor accusing anyone.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote